Mian B. Khalid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mian B. Khalid has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Peter Kofinas
University of Maryland
4 shared publications Aaron S. Fisher
Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, Maryland 20742, USA
3 shared publicationsSumera I. Ilyas
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
3 shared publications- Alexander H. Yang
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
2 shared publications - Anusha Vittal
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
2 shared publications - Bilal A. Asif
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
2 shared publications
Latest Publications
- 19 August 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (3) , 621-622
The road less traveled: Mapping the complex trajectories of PSC-IBD
Was not provided for this article.
- 19 August 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (3) , 621-622
The road less traveled: Mapping the complex trajectories of PSC-IBD
Was not provided for this article.
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , 3-4
What’s in a name? Reframing pediatric fatty liver disease in the Era of MASLD
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , 3-4
What’s in a name? Reframing pediatric fatty liver disease in the Era of MASLD
- 17 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 425-426
When the going gets tough, the tough keep scaling HIMALAYA
- 17 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 425-426
When the going gets tough, the tough keep scaling HIMALAYA
- 17 October 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (5) , 1039-1040
Surgical resection for hepatocellular carcinoma: Leave no TACE?
- 17 October 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (5) , 1039-1040
Surgical resection for hepatocellular carcinoma: Leave no TACE?
- 7 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 799-811
Evolving trends and comparative outcomes of bridging transarterial locoregional therapy in liver transplant candidates with hepatocellular carcinoma
Bridging locoregional therapy (LRT) is widely used in liver transplant (LT) candidates with hepatocellular carcinoma (HCC) to minimize waitlist dropout and evaluate tumor biology. While transarterial chemoembolization (TACE) has historically been the predominant approach, the role of transarterial radioembolization (TARE) is expanding. Comparative effectiveness data for these 2 modalities as bridging strategies remain limited. This study assessed the trends, factors influencing therapy selection, and outcomes of transarterial bridging LRT. We conducted a retrospective cohort study of adult LT candidates with HCC listed in the Organ Procurement and Transplantation Network (OPTN) between 2016 and 2024 who received TACE or TARE as their sole bridging LRT. Inverse probability weighting (IPW) was applied to balance baseline covariates. Multivariable Fine–Gray competing risk regression and stratified Cox proportional hazards and logistic regression models were used to assess waitlist dropout, complete pathological necrosis (CPN), recurrence, and overall survival. Among 8367 patients, 5472 (65%) received TACE, and 2895 (35%) received TARE. TARE use increased significantly from 22.5% to 51.7% over the study period. TARE was more likely to be used among patients with MASLD, older age, and high tumor burden, and less likely in those with lower socioeconomic status. TARE recipients had a significantly lower risk of waitlist dropout (sHR 0.83, p p p =0.19). The use of TARE as bridging therapy in HCC LT candidates has surged and is influenced by socioeconomic factors, comorbidities, and tumor burden. TARE effectiveness has been demonstrated by its advantages in waitlist retention and tumor necrosis. Further studies are warranted to evaluate its impact on post-LT recurrence and to validate the cost-effectiveness among transarterial therapies.
- 7 October 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 799-811
Evolving trends and comparative outcomes of bridging transarterial locoregional therapy in liver transplant candidates with hepatocellular carcinoma
Bridging locoregional therapy (LRT) is widely used in liver transplant (LT) candidates with hepatocellular carcinoma (HCC) to minimize waitlist dropout and evaluate tumor biology. While transarterial chemoembolization (TACE) has historically been the predominant approach, the role of transarterial radioembolization (TARE) is expanding. Comparative effectiveness data for these 2 modalities as bridging strategies remain limited. This study assessed the trends, factors influencing therapy selection, and outcomes of transarterial bridging LRT. We conducted a retrospective cohort study of adult LT candidates with HCC listed in the Organ Procurement and Transplantation Network (OPTN) between 2016 and 2024 who received TACE or TARE as their sole bridging LRT. Inverse probability weighting (IPW) was applied to balance baseline covariates. Multivariable Fine–Gray competing risk regression and stratified Cox proportional hazards and logistic regression models were used to assess waitlist dropout, complete pathological necrosis (CPN), recurrence, and overall survival. Among 8367 patients, 5472 (65%) received TACE, and 2895 (35%) received TARE. TARE use increased significantly from 22.5% to 51.7% over the study period. TARE was more likely to be used among patients with MASLD, older age, and high tumor burden, and less likely in those with lower socioeconomic status. TARE recipients had a significantly lower risk of waitlist dropout (sHR 0.83, p p p =0.19). The use of TARE as bridging therapy in HCC LT candidates has surged and is influenced by socioeconomic factors, comorbidities, and tumor burden. TARE effectiveness has been demonstrated by its advantages in waitlist retention and tumor necrosis. Further studies are warranted to evaluate its impact on post-LT recurrence and to validate the cost-effectiveness among transarterial therapies.
- 19 May 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (6) , 1627-1628
Apples and oranges: Parsing out ethnic disparities in MASLD
- 19 May 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (6) , 1627-1628
Apples and oranges: Parsing out ethnic disparities in MASLD
- 17 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (3) , 755-756
Deep learning: Cracking the metabolic code
- 17 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (3) , 755-756
Deep learning: Cracking the metabolic code
- 23 September 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (11) , e00770
Dynamics of Splenic Transient Elastography in Patients With Alcohol Use Disorder
INTRODUCTION: Splenic stiffness (SS) measurement (SSM) is an evolving noninvasive assessment to evaluate portal hypertension. Studies with respect to SSM in patients with alcohol use disorder are limited. METHODS: We studied patients seeking treatment for alcohol use disorder in an inpatient treatment protocol at the National Institutes of Health and parsed SSM into 3 groups based on degree of change. RESULTS: The improved SS group had statistically higher initial SSM and a nonstatistically increased liver stiffness measurement compared with others. DISCUSSION: SS is dynamic in a subset of patients immediately after alcohol cessation, and improved SS is associated with a normalization of platelet count.
- 23 September 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (11) , e00770
Dynamics of Splenic Transient Elastography in Patients With Alcohol Use Disorder
INTRODUCTION: Splenic stiffness (SS) measurement (SSM) is an evolving noninvasive assessment to evaluate portal hypertension. Studies with respect to SSM in patients with alcohol use disorder are limited. METHODS: We studied patients seeking treatment for alcohol use disorder in an inpatient treatment protocol at the National Institutes of Health and parsed SSM into 3 groups based on degree of change. RESULTS: The improved SS group had statistically higher initial SSM and a nonstatistically increased liver stiffness measurement compared with others. DISCUSSION: SS is dynamic in a subset of patients immediately after alcohol cessation, and improved SS is associated with a normalization of platelet count.
- 25 June 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2857-2860.e2
Gastrointestinal segmental remission with oral budesonide therapy for eosinophilic gastrointestinal diseases
- 25 June 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (10) , 2857-2860.e2
Gastrointestinal segmental remission with oral budesonide therapy for eosinophilic gastrointestinal diseases
- Open Access
- 12 April 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (5)
Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program
Background: Alcohol cessation is the only intervention that both prevents and halts the progressions of alcohol-associated liver disease. The aim of this study was to assess the relationship between a return to alcohol use and consultation with hepatology in treatment-seeking patients with alcohol use disorder (AUD). Methods: Two hundred forty-two patients with AUD were enrolled in an inpatient treatment program, with hepatology consultation provided for 143 (59%) patients at the request of the primary team. Patients not seen by hepatology served as controls. The primary outcome was any alcohol use after discharge assessed using AUDIT-C at 26 weeks after discharge. Results: For the primary endpoint, AUDIT at week 26, 61% of the hepatology group and 28% of the controls completed the questionnaire (p=0.07). For the secondary endpoint at week 52, these numbers were 22% and 11% (p = 0.6). At week 26, 39 (45%) patients in the hepatology group versus 31 (70%) controls (p = 0.006) returned to alcohol use. Patients evaluated by hepatology had decreased rates of hazardous alcohol use compared to controls, with 36 (41%) versus 29 (66%) (p = 0.008) of the patients, respectively, reporting hazardous use. There were no significant differences in baseline characteristics between groups and no difference in rates of prescribing AUD therapy. There was no difference in outcomes at 52 weeks. Conclusions: Patients evaluated by hepatology had significantly lower rates of return to alcohol use and lower rates of hazardous drinking at 26 weeks but not at 52 weeks. These findings suggest that hepatology evaluation during inpatient treatment of AUD may lead to decreased rates of early return to alcohol use.
- 12 April 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (5)
Open AccessHepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program
Background: Alcohol cessation is the only intervention that both prevents and halts the progressions of alcohol-associated liver disease. The aim of this study was to assess the relationship between a return to alcohol use and consultation with hepatology in treatment-seeking patients with alcohol use disorder (AUD). Methods: Two hundred forty-two patients with AUD were enrolled in an inpatient treatment program, with hepatology consultation provided for 143 (59%) patients at the request of the primary team. Patients not seen by hepatology served as controls. The primary outcome was any alcohol use after discharge assessed using AUDIT-C at 26 weeks after discharge. Results: For the primary endpoint, AUDIT at week 26, 61% of the hepatology group and 28% of the controls completed the questionnaire (p=0.07). For the secondary endpoint at week 52, these numbers were 22% and 11% (p = 0.6). At week 26, 39 (45%) patients in the hepatology group versus 31 (70%) controls (p = 0.006) returned to alcohol use. Patients evaluated by hepatology had decreased rates of hazardous alcohol use compared to controls, with 36 (41%) versus 29 (66%) (p = 0.008) of the patients, respectively, reporting hazardous use. There were no significant differences in baseline characteristics between groups and no difference in rates of prescribing AUD therapy. There was no difference in outcomes at 52 weeks. Conclusions: Patients evaluated by hepatology had significantly lower rates of return to alcohol use and lower rates of hazardous drinking at 26 weeks but not at 52 weeks. These findings suggest that hepatology evaluation during inpatient treatment of AUD may lead to decreased rates of early return to alcohol use.